Publications
Detailed Information
Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Do Heum | - |
dc.contributor.author | Bin, Seong-Il | - |
dc.contributor.author | Chan, Simon Kin-Cheong | - |
dc.contributor.author | Chung, Chun Kee | - |
dc.contributor.author | In, Yong | - |
dc.contributor.author | Kim, Hyoungmin | - |
dc.contributor.author | Lichauco, Juan Javier | - |
dc.contributor.author | Mok, Chi Chiu | - |
dc.contributor.author | Moon, Young-Wan | - |
dc.contributor.author | Ng, Tony Kwun-Tung | - |
dc.contributor.author | Penserga, Ester Gonzales | - |
dc.contributor.author | Shin, Dong Ah | - |
dc.contributor.author | You, Dora | - |
dc.contributor.author | Moon, Hanlim | - |
dc.date.accessioned | 2017-11-02T02:21:50Z | - |
dc.date.available | 2017-11-02T11:22:38Z | - |
dc.date.issued | 2017-08-04 | - |
dc.identifier.citation | BMC Musculoskeletal Disorders, 18(1):337 | ko_KR |
dc.identifier.issn | 1471-2474 | - |
dc.identifier.uri | https://hdl.handle.net/10371/138288 | - |
dc.description | AEs: Adverse events; BS-11: Box Scale-11; CIs: Confidence intervals; EAPC: European Association for Palliative Care; EQ VAS: EQ-5D visual analogue scale; EQ-5D-3 L questionnaire: EuroQol Group 5-Dimension SelfReport Questionnaire-3 Level Version Survey; GSQA: Global Sleep Quality Assessment Scale; ITT: Intent-to-treat; LS: Least squares; NICE: National Institute for Health and Care Excellence; NSAIDs: Nonsteroidal antiinflammatory drugs; PP: Per-protocol; SD: Standard deviation; TDB: Transdermal buprenorphine; TEAEs: Treatment-emergent adverse events | ko_KR |
dc.description.abstract | Abstract
Background We examined the effectiveness and tolerability of transdermal buprenorphine (TDB) treatment in real-world setting in Asian patients with musculoskeletal pain. Methods This was an open-label study conducted in Hong Kong, Korea, and the Philippines between June 2013 and April 2015. Eligible patients fulfilled the following criteria: 18 to 80years of age; clinical diagnosis of osteoarthritis, rheumatoid arthritis, low back pain, or joint/muscle pain; chronic non-malignant pain of moderate to severe intensity (Box-Scale-11 [BS-11] pain score≥4), not adequately controlled with non-opioid analgesics and requiring an opioid for adequate analgesia; and no prior history of opioid treatment. Patients started with a 5μg/h buprenorphine patch and were titrated as necessary to a maximum of 40μg/h over a 6-week period to achieve optimal pain control. Patients continued treatment with the titrated dose for 11weeks. The primary efficacy endpoint was the change in BS-11 pain scores. Other endpoints included patients sleep quality and quality of life as assessed by the 8-item Global Sleep Quality Assessment Scale (GSQA) questionnaire and the EuroQol Group 5-Dimension Self-Report Questionnaire-3 Level version (EQ-5D-3L), respectively. Tolerability was assessed by collecting adverse events. Results A total of 114 eligible patients were included in the analysis. The mean BS-11 score at baseline was 6.2 (SD 1.6). Following initiation of TDB, there was a statistically significant improvement in BS-11 score from baseline to visit 3 (least squares [LS] mean change: -2.27 [95% CI -2.66 to −1.87]), which was maintained till the end of the study (visit 7) (LS mean change: −2.64 [95% -3.05 to −2.23]) (p<0.0001 for both). The proportion of patients who rated sleep quality as good increased from 14.0% at baseline to 26.9% at visit 6. By visit 6, the mean EQ VAS score increased by 7.7units (SD 17.9). There were also significant improvements in patients levels of functioning for all EQ-5D-3L dimensions from baseline at visit 6 (p<0.05 for all). Seventy-eight percent of patients reported TEAEs and 22.8% of patients discontinued due to TEAEs. TEAEs were generally mild to moderate in intensity (96.5%). Conclusions TDB provides effective pain relief with an acceptable tolerability profile over the 11-week treatment period in Asian patients with chronic musculoskeletal pain. More studies are needed to examine the long-term efficacy and safety of TBD treatment in this patient population. | ko_KR |
dc.description.sponsorship | This study was funded by Mundipharma Pte Ltd., Singapore | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central | ko_KR |
dc.subject | Transdermal buprenorphine | ko_KR |
dc.subject | Asian | ko_KR |
dc.subject | Chronic non-malignant pain | ko_KR |
dc.subject | Musculoskeletal | ko_KR |
dc.subject | Pain score | ko_KR |
dc.subject | Quality of life | ko_KR |
dc.subject | Sleep quality | ko_KR |
dc.subject | Effectiveness | ko_KR |
dc.subject | Tolerability | ko_KR |
dc.title | Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 윤도흠 | - |
dc.contributor.AlternativeAuthor | 빈성일 | - |
dc.contributor.AlternativeAuthor | 정천기 | - |
dc.contributor.AlternativeAuthor | 인용 | - |
dc.contributor.AlternativeAuthor | 김형민 | - |
dc.contributor.AlternativeAuthor | 신동아 | - |
dc.contributor.AlternativeAuthor | 문한림 | - |
dc.identifier.doi | 10.1186/s12891-017-1664-4 | - |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s). | - |
dc.date.updated | 2017-10-03T16:49:58Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.